Hyperglycaemia in diabetes: Impact on nephropathy and cardiac risk

Nephrology Dialysis Transplantation

Volumn 18, Issue 9, 2003, Pages 1711-1715

  Torffvit, Ole ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiac risk; Diabetes; Hyperglycaemia; Nephropathy

Indexed keywords

ASPART; GLIBENCLAMIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFANILAMIDE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG MECHANISM; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; METABOLIC REGULATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; TREATMENT PLANNING;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HEART DISEASES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; PATIENT CARE MANAGEMENT; RISK FACTORS;

EID: 0041382919     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg213     Document Type: Article

References (53)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
2. Shichiri M, Ohkubo Y, Kishikawa H, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 [Suppl 2]: B21-B29
3. UK Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
4. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
5. Torffvit O, Agardh C-D. The impact of metabolic and blood pressure control on incidence and progression of nephropathy. A 10-year study of 385 type 2 diabetic patients. J Diabet Complications 2001; 15: 307-313
6. Torffvit O, Agardh C-D. The prognosis for type 2 diabetic patients with heart disease. A 10-year observation study of 385 Patients. J Diabet Complications 2000; 14: 301-306
7. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622
8. Sawicki P, Mühlhauser I, Didjurgeit U, Baumgartner A, Bender R, Berger M. Intensified antihypertensive therapy is associated with improved survival in type diabetic patients with nephropathy. J Hypertens 1995; 13: 933-938
9. Rachmani R, Levi Z, Slavachevski I, Avin M, Ravid M. Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with type 2 diabetes mellitus - a randomized prospective study. Diabet Med 2002; 19: 385-392
10. Torffvit O, Agardh CD. The impact of metabolic and blood pressure control on incidence and progression of nephropathy. A 10-year study of 385 type 2 diabetic patients. J Diabet Complications 2001; 15: 307-313
11. Hasslacher C, Stech W, Wahl P, Ritz E. Blood pressure and metabolic control as risk factors for nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 1985; 28: 6-11
12. Gall M-A, Nielsen F, Smidt U, Parving H-H. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 1993; 36: 1071-1078
13. Parving H-H. Diabetic nephropathy: prevention and treatment. Kidney Int 2001; 60: 2041-2055
14. Hasslacher C, Bostedt-Kiesel A, Kempe H, Wahl P. Effect of metabolic fators and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1051-1056
15. Bangstad H-J, Østerby R, Dahl-Jørgensen K, Berg K, Hartmann A, Hanssen KF. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483-490
16. Barbosa J, Steffes M, Sutherland D, Connett J, Rao K, Mauer S. Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. J Am Med Assoc 1994; 272: 600-606
17. Fioretto P, Steffes M, Sutherland D, Goetz F, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75
18. Feldt-Rasmussen B, Mathiesen E, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 1991; 34: 164-170
19. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 2001; 44: 2107-2114
20. The DECODE study group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-404
21. Balkau B, Forhan A, Eschwège E. Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia 2002; 45: 1224-1230
22. Pfeifer M, Halter J, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981; 70: 579-588
23. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-29
24. Ehrman D, Breda E, Cavaghan M et al. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia 2002; 45: 509-517
25. Eriksson K-F, Lindgärde F. Poor physical fitness, and impaired early insulin response but late hyperinsulinaemia, as predictors of NIDDM in middle-aged swedish men. Diabetologia 1996; 39: 573-579
26. Weyer C, Bogardus C, Tataranni P, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001; 24: 89-94
27. Kim D-J, Lee M-S, Kim K-W, Lee M-K. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism 2001; 50: 590-593
28. Bruttomesso D, Pianta A, Mari A et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99-105
29. Uchino H, Niwa M, Shimizu T, Nishiyama K, Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr J 2000; 47: 639-641
30. Miller J. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 1999; 10: 1778-1785
31. Ruggenenti P, Dodesini A, Flores C et al. Insulin lispro is better than regular insulin in limiting postprandial hyperglycemia and fully prevents meal-induced hyperfiltration in type 2 diabetics with overt nephropathy. Diabetes 2002; 51 [Suppl 2]: A191, 775-P
32. Rave K, Heinemann L, Heise T, Sawicki P, Pfützner A. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001; 24: 886-890
33. Milicevic Z, Herz M, Ivanyi T et al. Sulfonylurea (SU) and bedtime NPH insulin vs. Humalog Mix50 before breakfast and Humalog Mix25 before dinner in patients failing combined oral treatment. Diabetes 2002; 51 [Suppl 2]: A475, 1952-PO
34. Heinemann L, Heise T, Wahl L et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: Using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996; 13: 625-629
35. Andersson J, Brunelle R, Keohane P et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 1249-1255
36. Malone J, Woodworth J, Arora V et al. Improved postprandial glycemic control with Humalog Mix 75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 222-230
37. Chase H, MacKenzie T, Lockspeiser T et al. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001; 24: 430-434
38. Jungmann V, Helling T, Jungmann G, Mertens C, Snelting U. Intensivierte konventionelle insulintherapie (ICT) bei patienten mit typ 2 diabetes mellitus. Fortschr Med 2000; 118: 141-146
39. Home P, Lindholm A, Riis A, for the European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000; 17: 762-770
40. Perriello G, Avogaro A, Emanuele B, Squatrito S, Marra G, Cucinotta D. Superior meal-time glucose control with insulin Aspart (NovoLog) compared with human insulin in both normal-weight and overweight people with type 2 diabetes - a randomized, stratified, double-blind, crossover trial. Diabetes 2002; 51 [Suppl 2]: A111, 452-P
41. Klepzig H, Kober G, Matter C et al. Sulfonylureas and ischaemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-446
42. Scognamiglio R, Avogaro A, de Kreutzenberg S et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002; 51: 808-812
43. Siluk D, Kaliszan R, Haber P, Petrusewicz J, Brzozowski Z, Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 2002; 45: 1034-1037
44. Shakuto S, Sato Y, Oshima K, Yaguchi M. Preventive effect of a novel sulfonylurea, glimepiride (Amaryl) on experimental atherosclerosis. Diabetes 2002; 51 [Suppl 2]: A165, 2604-P
45. O'Keefe J, Blackstone E, Sergeant P, McCallister BD. The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J 1998; 19: 1696-1703
46. Olsson J, Lindberg G, Gottsäter M et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558-560
47. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001; 358: 1709-1716
48. Stumvoll M, Häring H-U. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-224
49. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J. Effects of Pioglitazone and Rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-396
50. Malmberg K, for the DIGAMI Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997; 314: 1512-1515
51. Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002; 45: 924-930
52. Rask-Madsen C, Ihlemann N, Krarup T et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 2001; 50: 2622-2628
53. Sundell J, Nuutila P, Laine H et al. Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes 2002; 51: 1125-1130